Navigation Links
Solid tumor cells not killed by radiation and chemotherapy become stronger
Date:6/9/2008

DURHAM, N.C. Because of the way solid tumors adapt the body's machinery to bring themselves more oxygen, chemotherapy and radiation may actually make these tumors stronger.

"In a sense, these therapies can make the tumor healthier," said Mark W. Dewhirst, D.V.M., Ph.D., professor of radiation oncology at Duke University Medical Center. "Unless the treatment is very effective in killing many if not most tumor cells, you are shooting yourself in the foot."

Dewhirst and colleagues Yiting Cao, M.D., Ph.D., of Duke Pathology, and Benjamin Moeller, M.D., Ph.D. have introduced this counter-intuitive idea at recent conferences and in a review article featured in the June issue of Nature Reviews Cancer.

Radiation and chemotherapy do kill most solid tumor cells, but in the cells that survive, the therapies drive an increase in a regulatory factor called HIF1 (hypoxia-inducible factor 1), which cells use to get the oxygen they need by increasing blood vessel growth into the tumor. Solid tumors generally have low supplies of oxygen, Dewhirst explained and HIF1 helps them get the oxygen they need.

The review article concludes that blocking HIF1 would provide a clear mechanism for killing solid-tumor cells, particularly cells that are proving resistant to radiation or chemotherapy treatments.

As a part of this work, Dewhirst's team has been studying the phenomenon of rising and falling oxygen levels in tumors, called cycling hypoxia. Oxygen levels have been found to naturally cycle up and down in individual blood vessels as well as large tumor regions. This instability in the tumor's oxygen levels can increase HIF-1 production and cause radiation therapy to fail, Dewhirst said.

"It is my opinion that the whole tumor grows more aggressively because of this pulsation of oxygen at low levels," Dewhirst said. "Most people thought cycling hypoxia was caused by temporary stoppage of blood flow in single blood vessel in
'/>"/>

Contact: Mary Jane Gore
mary.gore@duke.edu
919-660-1309
Duke University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. MedAmerica Reports Solid Growth, Outperforms Industry
2. Insurance Department to Hold Statewide Meetings on Proposed Consolidation of Independence Blue Cross, Highmark
3. STAAR Surgical Reports Solid First Quarter Progress
4. Life Sciences Discovery Fund Awards $2.2 Million to Support New Solid-Tumor Research Program
5. A long-term survival offered by resection of solid-pseudopapillary tumor of the pancreas?
6. New target for cancer therapy may improve treatment for solid tumors
7. Novo Nordisk Consolidates U.S. Diabetes Sales Leadership Under Single Vice President
8. Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007
9. SAFC Pharma Expands Its Pharmorphix Solid State Chemistry Services
10. Insurance Department Will Hold Public Hearings on Proposed Consolidation of Highmark, Independence Blue Cross
11. James E. Harris to Become Chief Financial Officer of Coca-Cola Bottling Co. Consolidated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...m workers are three times as likely as all other c...hildren to be uninsured, according to a report in ...lescent Medicine, one of the JAMA/Archives journal...health challenges, according to background informa... already has suboptimal access to pediatric health...
(Date:12/2/2008)...asylol have a higher death risk, data review finds...- A new study casts more doubt on the safety of th...g in patients undergoing surgery. , Trasylol is...States, where it was removed from the market in 20... researchers reviewed findings from 49 randomized ...
(Date:12/2/2008)...or Tuesday, December 2, 2008 at 3 pm CST)--Radiolo... University of South Carolina in Charleston, S.C.,...cer from exposure to radiation during computed tom...ated and that new estimates are several times lowe... researchers presented their findings at the annu...
(Date:12/2/2008)...PRNewswire-FirstCall/ -- United American Healthcar...rovides comprehensive healthcare,management servi...oday,announced that its Board of Directors has ap...e Company to repurchase up to $1.0 million of its ...lows for the Company,s common shares to be purchas...
Breaking Medicine News(10 mins):Health News:1/3 of farm workers' children lack health insurance 2Health News:Another Study Warns of Risk From Cardiac Surgery Drug 2Health News:Radiological Society of North America research: Cancer risk from cardiac CT overstated 2Health News:United American Healthcare Corporation Announces Stock Repurchase Program 2
...al food market is estimated at around $2.5 trillio...of four percent per annum. A radical shift in food...over. In markets, especially in the developed wor...the consumption of healthier foods is rapidly incr...
...test that detects proteins commonly released by a ...or monitoring the effectiveness of chemotherapy a...oat cancer, according to a study published in the ...er Research. Scientists in the National Institute...
...ers have found that patients with obstructive slee...d cells (apoptotic cells) from the lining (endothe...bloodstream than people who do not have OSA. The f...th OSA are at higher risk for cardiovascular disea...
...rospective study of 700 patients with culture-posi...o be significantly higher in HIV-infected patient...rifamycin-based regimen. Furthermore, TB relapse r...eived intermittent or standard 6-month therapy whe...
Other Medicine News:Health News:Nutrient-rich Dairy Beverages an Emerging Market 2Health News:Blood Test may Help Signal Tumor's Remission, Return in Throat Cancer Patients 2Health News:Blood Test may Help Signal Tumor's Remission, Return in Throat Cancer Patients 3Health News:Blood Test may Help Signal Tumor's Remission, Return in Throat Cancer Patients 4Health News:Patients With OSA at Higher Risk for Cardiovascular Disease 2Health News:Patients With OSA at Higher Risk for Cardiovascular Disease 3Health News:Treatment Outcomes of Patients With HIV and Tuberculosis 2
(Date:12/2/2008)..., Kan., Dec. 2 IBT Laboratories, a...arch laboratory specializing in immunology and all...ests to evaluate the response of patients whose i...immunodeficiency disorder, chemotherapy drugs, or ...o prevent rejection of a transplant. The company l...
(Date:12/1/2008)...O, Dec. 2 New research ...t-slice computed tomography (CT) scanner in an eme...of stroke victims who receive a potentially life-s...t North Shore Medical Center (NSMC)-Salem Hospital...nnual meeting of the Radiological Society of North...
(Date:12/1/2008)...ORE, Dec. 1 S*BIO Pte Ltd today an...al of SB1518, a potent and orally-active JAK2 inhi... patients with chronic idiopathic myelofibrosis (C...e the safety and tolerability of SB1518 in patient...ents. The Phase 1 part of the study will assess t...
(Date:12/1/2008)...Abstinence is still the best policy , , RO...A new study from Mayo Clinic finds the use of the ...coholic hepatitis, an acute inflammation of the li...e results of the study are published in the Decemb...journal.org/ ). , , VIDEO ALERT: Additiona...
Breaking Medicine Technology:IBT Laboratories Expands its Menu of Tests for Immune Deficiency 2Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3China Pharma Holdings Inc to Host Second Quarter 2008 Earnings Conference Call at 10 a m EDT Wednesday August 6 2008 6877 1China Pharma Holdings Inc to Host Second Quarter 2008 Earnings Conference Call at 10 a m EDT Wednesday August 6 2008 6877 2Strategies to control TB outdated inadequate 24851 1Strategies to control TB outdated inadequate 24851 2Immune system protein accurate predictor of survival in pediatric septic shock 4305 1Immune system protein accurate predictor of survival in pediatric septic shock 4305 2Immune system protein accurate predictor of survival in pediatric septic shock 4305 3HealthFitness Guides Incentives Strategy to Spark Participation in American Electric Power 26apos 3Bs Employee Health and Wellness Initiative New Issu 24849 1HealthFitness Guides Incentives Strategy to Spark Participation in American Electric Power 26apos 3Bs Employee Health and Wellness Initiative New Issu 24849 2HealthFitness Guides Incentives Strategy to Spark Participation in American Electric Power 26apos 3Bs Employee Health and Wellness Initiative New Issu 24849 3
...Sciences, Inc.,(Nasdaq:GILD) today announced detai...ing aztreonam lysine for inhalation, an,antibiotic...ulmonary Pseudomonas aeruginosa (P. aeruginosa). I...m lysine significantly improved,the time to need f...placebo. All patients received an initial 28 days ...
...x Pharmaceuticals,Inc. (OTCBB:CGXP), a biopharmac...dermatology, today announced the publication,of a ...al,compounds: CSA-8 and CSA-13. The paper appeared...l Agents and Chemotherapy, a,peer-reviewed officia... dedicated to advances in the field of applied,mic...
Other Medicine Technology:Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 2Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 3Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 5Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 6Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 7Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 2Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 3Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 4
VERSASTEP™ Reposable Short Single-Use For use with VERSASTEP™ Short Reusable Cannula, Dilator.
VersaStep™ Reposable Sterilization Trays.
VERSASTEP™ Plus Long Instrument for applications in laparoscopic procedures., ,The VERSASTEP™ Plus Long Instrument with 150mm Working Length is a unique endoscopic entry device that has
...ade; Blunt Tip Trocar consists of a blunt obturato... , ,The valve body assembly contains an internal ... instruments are inserted or withdrawn. The Autosu...verters to allow insertion of instruments of diffe...
Medicine Products: